<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494387</url>
  </required_header>
  <id_info>
    <org_study_id>VIXIE2018</org_study_id>
    <nct_id>NCT03494387</nct_id>
  </id_info>
  <brief_title>VitamIn and oXygen Interventions and Cardiovascular Events</brief_title>
  <acronym>VIXIE</acronym>
  <official_title>Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the risks and benefits of antioxidants and normal versus high inspiratory
      oxygen fraction during anaesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with risk factors for developing postoperative cardiac complications will be
      enrolled in the study. The patients will be randomised to receiving antioxidants or placebo
      perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2
      hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac
      surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively
      and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours,
      starting at the same time as anaesthesia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial injury after non-cardiac surgery (MINS)</measure>
    <time_frame>30 days</time_frame>
    <description>Troponin measurement the first 3 postoperative days. Assessed by area under the curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Serious Adverse Event</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Infection in surgical area as defined by the Center for Disease Control</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumonia</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Pneumonia as defined by the Center for Disease Control</description>
  </other_outcome>
  <other_outcome>
    <measure>Sepsis</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute respiratory failure</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Postoperative Cardiac Complication</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>80% versus 30% inspiratory oxygen concentration</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidants</intervention_name>
    <description>Antioxidants versus placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Ascorbic acid</other_name>
    <other_name>N-acetylcysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        All of the listed criteria (1.-4.) must be met.

          1. Age 45 years or above

          2. Elective or acute surgery in general anaesthesia

          3. Scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery
             duration of one hour or more.

          4. Fulfil any 1 of the following 5 criteria:

               1. - History of coronary artery disease including angina

               2. - History of stroke

               3. - Undergoing vascular surgery

               4. - History of peripheral arterial disease

               5. - Any 2 of the following 8 criteria: i. Acute surgery ii. Current or previous
                  daily smoking iii. History of hypertension iv. Diabetes mellitus requiring
                  medical treatment v. History of transient cerebral ischemia vi. Plasma creatinine
                  &gt;175 ÂµM vii. Age 70 years or above viii. History of congestive heart failure

        Exclusion criteria:

          1. Surgery within 30 days prior to operation

          2. Arterial oxygen saturation below 90% without oxygen supplementation

          3. Inability to give informed consent

          4. Drug allergy towards any of the drugs involved in the trial

          5. Previous treatment with bleomycin

          6. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Meyhoff, PhD</last_name>
    <phone>004520341452</phone>
    <email>christian.sahlholt.meyhoff@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg and Frederiksberg Hospital, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilie Petersen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Cecilie Petersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Antioxidant</keyword>
  <keyword>Hyperoxia</keyword>
  <keyword>Troponin</keyword>
  <keyword>MINS</keyword>
  <keyword>Ascorbic acid</keyword>
  <keyword>N-acetylcysteine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

